Assembly Biosciences

About Assembly Assembly Biosciences, Inc. is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's proprietary Core Protein Allosteric Modulators (CpAMs) are small molecule, oral agents for the treatment of viral infections. The company's lead program focuses on hepatitis B (HBV), which infects an estimated 350 million people worldwide and is associated with 600,000 deaths annually. CpAMs alter the HBV core protein, a unique target that is essential to the functioning of the virus. Unlike current therapies that only suppress HBV, CpAMs may have curative potential. Assembly also is developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections.
Company Growth (employees)
Type
Public
HQ
New York, US
Founded
2007
Size (employees)
51 (est)
Assembly Biosciences was founded in 2007 and is headquartered in New York, US

Assembly Biosciences Office Locations

Assembly Biosciences has offices in New York, Carmel, Bloomington and San Francisco
New York, US (HQ)
101 Sixth Avenue 9th Floor
San Francisco, US
409 Illinois St
Bloomington, US
212 S. Hawthorne Drive
Carmel, US
310 11711 N Meridian St

Assembly Biosciences Financials and Metrics

Assembly Biosciences Financials

USD

Net income (Q2, 2017)

(13.6 m)

EBIT (Q2, 2017)

(13.6 m)

Market capitalization (13-Nov-2017)

579 m

Cash (30-Jun-2017)

39.5 m
Assembly Biosciences's current market capitalization is $579 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

33.1 m

General and administrative expense

12.2 m

Operating expense total

45.3 m

EBIT

(98.2 m)(24 m)(29.7 m)(45.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

1.1 m3.7 m3.8 m4.7 m4.6 m8.1 m7.5 m8.8 m10.6 m12.1 m

General and administrative expense

1.4 m7.4 m3.4 m2.5 m2.5 m3.2 m2.9 m2.8 m4 m3.8 m

Operating expense total

2.5 m11.1 m7.2 m7.2 m7.1 m11.3 m10.5 m11.7 m14.6 m15.9 m

EBIT

(2.5 m)(11.1 m)(7.2 m)(7.2 m)(7.1 m)(11.3 m)(10.5 m)(11.7 m)(13.9 m)(13.6 m)
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

81.3 k14.6 m37 m20.5 m27.1 m29.1 m27.1 m28.6 m

Inventories

611.2 k

Current Assets

27.1 m29.2 m68.4 m53.6 m

PP&E

156.4 k148.6 k214.7 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

21.3 m17.9 m96.1 m53.5 m36.4 m20.4 m20.3 m23.8 m70.8 m39.5 m

Accounts Receivable

1.1 m

Current Assets

21.7 m18.1 m96.3 m71.3 m66.5 m59.1 m64.1 m59.3 m92.2 m77.7 m

PP&E

173.2 k174 k156.5 k132.2 k113.7 k128.5 k182.8 k131.9 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(23.8 m)(28.5 m)(44.3 m)

Depreciation and Amortization

6.2 k11 k65 k80.3 k

Inventories

93.1 k

Accounts Payable

(107.4 k)(2.5 m)456.1 k1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)(27.5 m)

Accounts Payable

2.3 m1.4 m1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m
Y, 2017

Financial Leverage

2.2 x
Show all financial metrics

Assembly Biosciences Market Value History

Assembly Biosciences's Web-traffic and Trends

Assembly Biosciences Company Life and Culture

You may also be interested in